125P A phase IIa study of the novel immunogenic cell death (ICD) inducer PT-112 plus avelumab (“PAVE”) in advanced non-small cell lung cancer (NSCLC) patients (pts)
| Autor: | Imbimbo, M., Ghisoni, E., Mulvey, A., Bouchaab, H., Mederos Alfonso, N., Karp, D., Camidge, D.R., Mansfield, A.S., Yim, C.Y., Ames, T.D., Price, M., Baeck, J., O'Donnell, J.F., Peters, S. |
|---|---|
| Zdroj: | In Immuno-Oncology and Technology December 2022 16 Supplement 1 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|